Dr. Reddy's Laboratories Limited

rs,

Governments in our key global markets; ▪ Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry; ▪ Increasing competition in and the conditions of our

₹ 8,805

nder IFRS Q2FY26 Financial Highlights Near double-digit growth and steady profitability Revenues ₹ 8,805 Cr 9.8%YoY 3%QoQ EBITDA | EBITDA % ₹ 2,351 Cr | 26.7% Impairment: in Middleburg due to DP UNDE

9.8%

2FY26 Financial Highlights Near double-digit growth and steady profitability Revenues ₹ 8,805 Cr 9.8%YoY 3%QoQ EBITDA | EBITDA % ₹ 2,351 Cr | 26.7% Impairment: in Middleburg due to DP UNDERLYING F

3%

ancial Highlights Near double-digit growth and steady profitability Revenues ₹ 8,805 Cr 9.8%YoY 3%QoQ EBITDA | EBITDA % ₹ 2,351 Cr | 26.7% Impairment: in Middleburg due to DP UNDERLYING FINANCIA

₹ 2,351

uble-digit growth and steady profitability Revenues ₹ 8,805 Cr 9.8%YoY 3%QoQ EBITDA | EBITDA % ₹ 2,351 Cr | 26.7% Impairment: in Middleburg due to DP UNDERLYING FINANCIALS (adjusted for One-off) • Re

26.7%

owth and steady profitability Revenues ₹ 8,805 Cr 9.8%YoY 3%QoQ EBITDA | EBITDA % ₹ 2,351 Cr | 26.7% Impairment: in Middleburg due to DP UNDERLYING FINANCIALS (adjusted for One-off) • Revenue grow

27.5%

urg due to DP UNDERLYING FINANCIALS (adjusted for One-off) • Revenue growth @9.8% Underlying % 27.5% 21.6% 3%YoY 3%QoQ • Reported EBITDA Margin @26.7% • Annualised RoCE at ~22% • Net Cash surplu

21.6%

to DP UNDERLYING FINANCIALS (adjusted for One-off) • Revenue growth @9.8% Underlying % 27.5% 21.6% 3%YoY 3%QoQ • Reported EBITDA Margin @26.7% • Annualised RoCE at ~22% • Net Cash surplus at ₹

22%

% Underlying % 27.5% 21.6% 3%YoY 3%QoQ • Reported EBITDA Margin @26.7% • Annualised RoCE at ~22% • Net Cash surplus at ₹ 2,751 Cr 4,814 8,805 54.7% 2,351 26.7% 26.7% 1,835 20.8% 20.8% R

₹ 2,751

6% 3%YoY 3%QoQ • Reported EBITDA Margin @26.7% • Annualised RoCE at ~22% • Net Cash surplus at ₹ 2,751 Cr 4,814 8,805 54.7% 2,351 26.7% 26.7% 1,835 20.8% 20.8% Revenues EBITDA% PBT% Reported

54.7%

ed EBITDA Margin @26.7% • Annualised RoCE at ~22% • Net Cash surplus at ₹ 2,751 Cr 4,814 8,805 54.7% 2,351 26.7% 26.7% 1,835 20.8% 20.8% Revenues EBITDA% PBT% Reported One-offs attributable

20.8%

ed RoCE at ~22% • Net Cash surplus at ₹ 2,751 Cr 4,814 8,805 54.7% 2,351 26.7% 26.7% 1,835 20.8% 20.8% Revenues EBITDA% PBT% Reported One-offs attributable to VAT provision PBT | PBT % ₹ 1,